A Study to Understand the Safety of the 20vPnC Vaccine in Healthy Chinese Adults, Children, and Infant

Launched by PFIZER · Jun 8, 2025

Keywords

ClinConnect Summary

This clinical trial is designed to learn about the safety of a new vaccine called the 20-valent pneumococcal conjugate vaccine (20vPnC) in healthy people of different ages. Pneumococcal disease can cause serious infections, and this study aims to see how well the vaccine works and whether it is safe for adults, children, and infants in China. The trial will include five groups of participants: adults aged 18 to 50, children aged 2 to 6, children aged 12 months to 2 years, infants aged 7 to 12 months, and very young infants aged 42 to 98 days. Each group will receive a specific number of vaccine doses based on their age.

If you or a family member is healthy and falls into one of these age groups, you may be eligible to participate in the study. Participants will have several visits over a period ranging from about 6 months to nearly 19 months, depending on their age group. During these visits, the researchers will monitor how participants respond to the vaccine. It’s important to note that individuals with certain health conditions or previous allergic reactions to vaccines may not be eligible. If you're interested or want more details, please reach out to the study contact for more information.

Gender

ALL

Eligibility criteria

• Key inclusion criteria:
• * Male or female participants:
• • Adults ≥18 to \<50 years of age
• • Children ≥2 to \<6 years of age
• • Children ≥12 months to \<2 years of age
• • Infants ≥7 to \<12 months of age
• • Infants ≥42 to ≤98 days of age
• • Healthy participants determined by clinical assessment and clinical judgment, to be eligible for the study.
• Key exclusion criteria:
• • History of severe adverse reaction associated with a vaccine and/or severe allergic reaction (eg, anaphylaxis) to any component of the study intervention, or any diphtheria toxoid-containing vaccine.
• • History of microbiologically proven invasive disease caused by S pneumoniae.
• • Congenital, functional, or surgical asplenia.
• • Previous vaccination with any licensed or investigational pneumococcal vaccine, or planned receipt during study participation.
• • Determined as not eligible by the investigator based on the participant's past and present health condition(s), medication(s) and treatment(s).
• • Please refer to the study contact for further eligibility details.